All Data
Sanofi Active Ingredient Solutions cover both APIs sales & CDMO.
Lead Product(s): Dupilumab
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Dupixent
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2020
Details:
DUPIXENT® is a fully humanised monoclonal antibody that inhibits signaling of IL-4 and IL-13 proteins and is not an immunosuppressant. It is the only biologic approved in Canada to treat severe asthma with type 2/eosinophilic phenotype, or oral corticosteroid-dependent asthma.
Sanofi Active Ingredient Solutions cover both APIs sales & CDMO.
Lead Product(s): Dupilumab
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Dupixent
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2020
Details:
Health Canada approved a new indication for Dupixent, as an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyposis (CRSwNP) inadequately controlled by systemic corticosteroids and/or surgery.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
